Tacrolimus pharmacokinetics of once-versus twice-daily formulations in de novo kidney transplantation: A substudy of a randomized phase III trial

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 143-147

  Wlodarczyk, Zbigniew ^a   Ostrowski, Marek ^b   Mourad, Michel ^c   Krämer, Bernhard K ^d,e   Abramowicz, Daniel ^f   Oppenheimer, Federico ^g   Miller, Derek ^h   Dickinson, James ⁱ   Undre, Nasrullah ^j  

^a Antoni Jurasz University Hospital   (Poland)

^b General and Transplantology Surgery   (Poland)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f ERASME HOSPITAL   (Belgium)

^g HOSPITAL CLÍNIC   (Spain)

^h Christiaan Barnard Memorial Hospital   (South Africa)

ⁱ Astellas Pharma Global Development   (Netherlands)

^j ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

more..

Author keywords

kidney; oncedaily tacrolimus; prolonged release; tacrolimus; transplant

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; EVENING DOSAGE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS;

EID: 84862806052     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824d1620     Document Type: Article

References (12)

1. Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10:2313-2323.
2. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extendedrelease tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7:595-608. (Pubitemid 46376444)
3. Krämer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010;10: 2632-2643.
4. Srinivas TR, Kaplan B, Meier-Kriesche HU. The noninferiority trial: don't don't do it. Am J Transplant. 2010;10:2571-2573.
5. Scott LJ,McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-1297. (Pubitemid 36750952)
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653. (Pubitemid 38981845)
7. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
8. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009; 9:2505-2513.
9. Fischer L, Trunecka P, Gridelli B, et al. Pharmacokinetics for onceversus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl. 2011;17:167-177.
10. Alak AM, Moy S, Cook M, et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. J Pharm Biomed Anal. 1997;16:7-13. (Pubitemid 27462682)
11. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London, January 20, 2010. Doc Ref: CPMP/EWP/QWP/1401/98 Rev. 1/Corr**.
12. Iwahori T, Takeuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc. 2005;37:1739-1740. (Pubitemid 40790815)